Vaccine Guidance

The JYNNEOS vaccine has been provided at no cost from the Federal Government since Summer 2022 in response to the mpox outbreak. As of April 2, 2024, JYNNEOS has started transitioning to the commercial market. See the Role of Healthcare Provider in the Mpox Vaccination Response section of this webpage for more information.

Cases of mpox peaked in August 2022, but the outbreak is not over. CDC continues to receive reports of cases that reflect ongoing community transmission in the U.S. and internationally, including multiple jurisdictions in the U.S. Virginia recently reported an increase in mpox cases. 

CDC and VDH are urging clinicians to be on the alert for new cases of mpox (even if someone has been partially or fully vaccinated for mpox) and to encourage vaccination for people at risk.

Although vaccine-induced immunity is not complete, vaccination continues to be one of the most important prevention measures. CDC expects new cases among previously vaccinated people to occur, but people who have completed their two-dose JYNNEOS vaccine series have less severe symptoms and are less likely to be hospitalized than those who have not been vaccinated.

Mpox vaccination, testing, and treatment should be incorporated into routine care, including sexual health and HIV care services. CDC also has guidance to help with planning and implementation of satellite, temporary, and off-site vaccination clinics by public and private vaccination organizations. Resources include:

Page updated:  April 24, 2024

Opens pdf to download

Opens document to download

Opens in a new window

External link will open in a new window.  Click link to exit Virginia Department of Health Website.